Semaglutide, marketed under the brand names Wegovy (for weight loss) and Ozempic (for type 2 diabetes), currently accounts for 25 per cent of the total Rs 1,579 crore GLP-1 agonist market in India and a potential label expansion gives the company room to tap a new market, insulated from generics and Eli Lillys Mounjaro (tirzepatide), which swept the category last year in both value and volume share
Retnakaran, R., Kramer, C
Theyre easy to pop into your morning routine and widely accessible
Common: mild site redness, initial headaches
Can glutathione help with melasma
Given the complexity of the model, it was not possible within the review time frame to verify all the code and assess how the data inputs generated the model outcomes